Business
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -- Presenting at the 44th Annual J.P.
About this update from Edgewise Therapeutics, Inc.
[{"type":"text","content":"- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -- Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 am PT (11:15 am ET) -BOULDER, Colo., Jan. 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided updates on the Company's clinical programs and highlighted major milestones for 2026. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the J.P. Morgan 2026 Healthcare Conference.\n \n \n \n \n \n \n \n\"2025 marked a year of disciplined execution and substantial advances in our skeletal and cardiovascular programs, supported by a strong balance sheet,\" said Dr. Koch. \"Entering 2026, our Company is poised for a transformative year. With full enrollment in our pivotal GRAND CANYON cohort, we remain on track for top-line data that could help establish sevasemten as the first approved therapy in Becker muscular dystrophy (Becker), potentially altering the course of this devastating disease. In parallel, we anticipate Phase 2 results for EDG-7500 in hypertrophic cardiomyopathy (HCM) in the first half of the year, that will enable us to finalize designs for our Phase 3 program in obstructive and nonobstructive HCM. Backed by multiple near-term catalysts and an exceptional team committed to excellence, we are closer than ever to bringing transformative medicines to patients who urgently need them.\"2026 PrioritiesSevasemten Complete the GRAND CANYON global pivotal cohort and announce top-line results in individuals with Becker in the fourth quarter of 2026.Prepare for submission of a New Drug Application with the U.S. Food and Drug Administration for sevasemten in Becker in the first half of 2027.Finalize the design and plan for a Phase 3 trial in individuals with Duchenne muscular dystrophy (Duchenne) in the second half of 2026.EDG-7500 Report CIRRUS-HCM 12-week data in individuals with obstructive and nonobstructive HCM in the first half of 2026.Initiate a Phase 3 trial in individuals with obstructive and nonobstructive HCM in the second half of 2026.EDG-15400 Report Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose data of EDG-15400 in healthy adults in the firs...